Abstract
We read with interest the recent article by Jacobsen et al<sup>1</sup>on the predictive properties of prostate-specific antigen (PSA) as a screening test for prostate cancer in a population-based setting. This study demonstrates an important point when considering operating characteristics of screening or diagnostic tests when used with different populations. In the urology practice setting, the prevalence of prostate cancer and benign prostate disease (a primary source of false-positive results) is far higher than in the general population. It should be expected that the specificity of the screening test will be greater in the general population, where there are proportionately fewer men with benign disease and more men free of disease. In community-based and primary care settings, the distributions of PSA levels among men with and without prostate cancer are more disparate than in the specialty setting. We want to draw attention to 2 additional points that are crucial
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.